Monogenic synaptic collapse and bottleneck of a penetrant triadic phenotype. SYNGAP1‑related disorder (SRD) is a prototypical monogenic synaptopathy caused by loss‑of‑function of a single allele of the SYNGAP1 gene, which encodes the Ras GTPase‑activating protein, a core component of the postsynaptic density (PSD). This haploinsufficiency simultaneously triggers a highly penetrant triad of intellectual disability, generalized epilepsy, and autism‑spectrum behavioral abnormalities. The disorder manifests early with global developmental delay and hypotonia, representing a lethal molecular‑biological bottleneck that quantitatively delineates the genetic limits of neural network formation during brain development.

Ras/Rap‑ERK signaling surge and early cortical hard‑wiring. At the molecular level, loss of SynGAP protein leads to abnormal hyperactivation of downstream Ras/Rap‑ERK pathways. This surge accelerates the maturation cycle of dendritic spines, depriving immature synapses of the opportunity for activity‑dependent fine‑tuning and driving premature hard‑wiring of cortical circuits. Concurrently, AMPA‑receptor trafficking kinetics are disrupted and the structural stability of the PSD architecture is compromised, resulting in irreversible inhibition of synaptic plasticity and long‑term potentiation (LTP) and causing permanent alterations in oscillatory dynamics.

Clinical regression of drug‑resistant reflex epilepsy and multi‑omics biomarker mapping. Clinically, affected children experience atypical absences, myoclonic seizures, and reflex seizures triggered by eye‑closure, fixation‑off, or eating, as well as eyelid‑myoclonia. Resistance to conventional antiepileptic drugs is exceedingly high, and worsening seizure burden and EEG patterns directly precipitate regression of cognitive and language development. To quantitatively track severe phenotypes, a scalable biomarker pipeline integrating genomic data, quantitative EEG (qEEG), digital eye‑tracking, and gait‑metric analyses has been introduced into the clinical validation layer, enhancing prognostic resolution.

Implementation of a precision‑therapeutics paradigm and acceleration of clinical approval. The synaptic structural biology and clinical phenomics dataset generated here provides a uniquely powerful asset for the global nucleic‑acid drug R&D sector and next‑generation gene‑editing enterprises. Beyond symptomatic management with valproate or lamotrigine, the dataset underpins a clinical‑trial backbone for precision approaches such as SYNGAP1 allele‑specific expression restoration via antisense oligonucleotides (ASOs), CRISPR‑based gene correction, and small‑molecule modulators of circuit plasticity. By integrating patient genotype screening with qEEG dynamic profiling, the platform enables virtual computation of reversible developmental‑recovery thresholds, establishing a reference standard for next‑generation precision‑medicine frameworks.